CA2541162A1 - Fused lactam compounds - Google Patents
Fused lactam compounds Download PDFInfo
- Publication number
- CA2541162A1 CA2541162A1 CA002541162A CA2541162A CA2541162A1 CA 2541162 A1 CA2541162 A1 CA 2541162A1 CA 002541162 A CA002541162 A CA 002541162A CA 2541162 A CA2541162 A CA 2541162A CA 2541162 A1 CA2541162 A1 CA 2541162A1
- Authority
- CA
- Canada
- Prior art keywords
- hydroxy
- group
- dihydroquinolin
- carbon atoms
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50967003P | 2003-10-08 | 2003-10-08 | |
US60/509,670 | 2003-10-08 | ||
PCT/IB2004/003125 WO2005035523A1 (en) | 2003-10-08 | 2004-09-27 | Fused lactam compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2541162A1 true CA2541162A1 (en) | 2005-04-21 |
Family
ID=34435007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002541162A Abandoned CA2541162A1 (en) | 2003-10-08 | 2004-09-27 | Fused lactam compounds |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1673367A1 (pt) |
JP (1) | JP2007508288A (pt) |
BR (1) | BRPI0415113A (pt) |
CA (1) | CA2541162A1 (pt) |
MX (1) | MXPA06003748A (pt) |
WO (1) | WO2005035523A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1736474A4 (en) * | 2004-04-07 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | piperidine |
US8946267B2 (en) | 2010-07-30 | 2015-02-03 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for neuropathic pain |
KR20140146217A (ko) | 2012-04-20 | 2014-12-24 | 유씨비 파마, 에스.에이. | 파킨슨병을 치료하는 방법 |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
US9221796B2 (en) | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
US10159648B2 (en) | 2015-05-22 | 2018-12-25 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
MX2018004257A (es) | 2015-10-14 | 2018-05-16 | Squibb Bristol Myers Co | Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0163355B1 (ko) * | 1990-05-10 | 1998-12-01 | 알렌 제이. 스피겔 | 신경보호성 인돌론 및 관련 유도체 |
AU655840B2 (en) * | 1991-07-17 | 1995-01-12 | Pfizer Inc. | 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents |
FR2688504B1 (fr) * | 1992-03-13 | 1995-05-05 | Synthelabo | Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique. |
CZ280669B6 (cs) * | 1992-10-30 | 1996-03-13 | Pfizer Inc. | Deriváty 3,4-dihydro-2(1H)-chinolonu a farmaceutický prostředek na jejich bázi |
US5498610A (en) * | 1992-11-06 | 1996-03-12 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
US6713490B2 (en) * | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
-
2004
- 2004-09-27 BR BRPI0415113-5A patent/BRPI0415113A/pt not_active IP Right Cessation
- 2004-09-27 JP JP2006530731A patent/JP2007508288A/ja not_active Withdrawn
- 2004-09-27 CA CA002541162A patent/CA2541162A1/en not_active Abandoned
- 2004-09-27 MX MXPA06003748A patent/MXPA06003748A/es unknown
- 2004-09-27 EP EP04769480A patent/EP1673367A1/en not_active Withdrawn
- 2004-09-27 WO PCT/IB2004/003125 patent/WO2005035523A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2005035523A1 (en) | 2005-04-21 |
MXPA06003748A (es) | 2006-06-14 |
JP2007508288A (ja) | 2007-04-05 |
BRPI0415113A (pt) | 2006-11-28 |
EP1673367A1 (en) | 2006-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7279486B2 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | |
EP1756042B1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
EP1756043B1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
US20040204409A1 (en) | Bicyclic compounds as NR2B receptor antagonists | |
WO2006016218A1 (en) | Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists | |
CA2555970A1 (en) | Therapeutic amide derivatives | |
CA2541162A1 (en) | Fused lactam compounds | |
US20070021414A1 (en) | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | |
WO2005095329A1 (en) | Substituted benzamide compounds as vr1 receptor antagonists | |
US20040152715A1 (en) | Cycloalkylene amide compounds as NR2B receptor antagonists | |
MXPA06009685A (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |